改良预处理方式下那西妥单抗治疗神经母细胞瘤安全性研究  

Safety study of naxitamab infusion for neuroblastoma under modified conditioning regimen

作　　者：朱佳[1] 邓军 阙旖 刘龙珍 伍柳红 余婉琪 管惠捷 王娟[1] 路素英[1] 孙斐斐[1] 黄俊廷[1] 宋梦佳 甄子俊[1] 蔡瑞卿[1] 张翼鷟 Jia Zhu;Jun Deng;Yi Que;Longzhen Liu;Liuhong Wu;Wanqi Yu;Huijie Guan;Juan Wang;Suying Lu;Feifei Sun;Junting Huang;MengjiaSong;Zijun Zhen;Ruiqing Cai;Yizhuo Zhang(Department of Pediatric Oncology,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Guangdong Provincial Clinical Research Center for Cancer,Guangzhou 510060,China)

机构地区：[1]中山大学肿瘤防治中心儿童肿瘤科,华南恶性肿瘤防治全国重点实验室,广东省恶性肿瘤临床医学研究中心,广州市510060

出　　处：《中国肿瘤临床》2024年第22期1154-1158,共5页Chinese Journal of Clinical Oncology

摘　　要：目的:糖皮质激素具有潜在影响那西妥单抗免疫效应,氯胺酮有抑制呼吸副作用。本研究探讨去除糖皮质激素,瑞芬太尼代替氯胺酮的预处理方式对那西妥单抗输注不良事件发生的影响。方法:收集2023年6月至2024年6月于中山大学肿瘤防治中心接受那西妥单抗输注的神经母细胞瘤患者临床资料,分析改良预处理后不良事件发生率以及相关因素。结果:17例患者接受201次输注,最常见不良反应为各级别神经痛(93.0%)、高血压(55.7%)、低血压(34.8%)。支气管痉挛和低氧血症的发生率分别为3.0%和10.9%。连续2个周期输注中,发热发生率下降。无患者因严重输注不良反应停止治疗。结论:经改良预处理支持下,那西妥单抗输注不良反应低且可控,安全性好。Objective:Glucorticoid therapy has the potential to mitigate immunogical effect of naxitamab.Ketamine is an anesthetic medica-tion and cause weak or shallow breathing.This article is to analyze the effect of modified conditioning regimen with substitution re-mifentanil for ketamine and without glucorticoid therapy on adverse events associated with naxitamab.Methods:Clinical data with naxit-amab infusion under modified conditioning regimen in Sun Yat-sen University Cancer Center between June 2023 and June 2024 were re-trieved to analyze adverse events and risk factors.Results:Overall,seventeen patients underwent 201 infusions.The most frequent adverse events were as follows:neurological pain(all grades)93.0%,hypertension 55.7%,hypotension 34.8%,respectively.Bronchospasm and hyp-oxia were seen in 3.0%and 10.9%infusions,respectively.Fever occurred less frequently in the second cycle of infusion.No patients suspen-ded infusion due to severe adverse event.Conclusions:The infusion of naxitamab is tolerable under the modified conditioning regimen and adverse event is less than expected and controllable.

关 键 词：纳洛酮 不良反应事件 儿童 神经母细胞瘤 改良调理方案 

分 类 号：R739.4[医药卫生—肿瘤]